Topamax and Peginterferon drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Topamax and Peginterferon. Common interactions include anaemia among females and anaemia among males.

The phase IV clinical study analyzes what interactions people who take Topamax and Peginterferon have. It is created by eHealthMe based on reports of 12 people who take Topamax and Peginterferon from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 24, 2023

12 people who take Topamax and Peginterferon together, and have interactions are studied.

What is Topamax?

Topamax has active ingredients of topiramate. It is often used in migraine. eHealthMe is studying from 55,079 Topamax users for its effectiveness, alternative drugs and more.

What is Peginterferon?

Peginterferon has active ingredients of peginterferon alfa-2a; ribavirin. It is often used in hepatitis c. eHealthMe is studying from 13,679 Peginterferon users for its effectiveness, alternative drugs and more.

Number of Topamax and Peginterferon reports submitted per year:

Common Topamax and Peginterferon drug interactions by gender *:

female:

Anaemia
Rash
Renal failure acute
Allergic transfusion reaction
Asthenia
Blood bilirubin increased
Chest discomfort
Convulsion
Dizziness
Drug hypersensitivity

male:

Anaemia
Ascites
Nephrolithiasis
Pathogen resistance
Pleural effusion
Pneumonia
Pyrexia
Renal failure
Respiratory distress
Respiratory failure

Common Topamax and Peginterferon drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Anaemia
Ascites
Aspergillus test positive
Coagulopathy
Device related infection
Escherichia test positive
General physical health deterioration
Hepatic failure
Multi-organ failure
Multiple-drug resistance

50-59:

Anaemia
Dizziness
Hypotension
Infection
Nausea
Rash

60+:

Anaemia
Fall
Pubis fracture
Syncope

Common conditions people have *:

Headache (pain in head): 2 people, 16.67%
Nausea (feeling of having an urge to vomit): 2 people, 16.67%
Hiv Infection: 2 people, 16.67%
High Blood Pressure: 2 people, 16.67%
Type 2 Diabetes: 1 person, 8.33%
Birth Control: 1 person, 8.33%
Breathing Difficulty: 1 person, 8.33%
Constipation: 1 person, 8.33%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 1 person, 8.33%
Depression: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Topamax and Peginterferon?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Baloch M, Siddiqui MA, "Topiramate induced sudden loss of vision", JPMA, 2012 Oct .
Kocamaz, M., & Karadag, O., "Topiramate-Induced Acute Myopia, Diplopia, and Photosensitivity: A Case Report", Beyoglu Eye Journal, 2019 Jan .